PDLIM1P4: A Potential Drug Target and Biomarker (G100419185)

Target Name: PDLIM1P4

NCBI ID: G100419185

PDLIM1P4

Other Name(s): PDZ and LIM domain 1 pseudogene 4

PDLIM1P4: A Potential Drug Target and Biomarker

Platelet-derived life-longing (PDL) domain-containing proteins, also known as PLDPs, are a family of transmembrane proteins that play a crucial role in hematopoietic stem cell (HSC) maintenance and proliferation. PDLPs have been implicated in a wide range of physiological processes, including blood clotting, thrombosis, and immune regulation. In recent years, the study of PDLPs has gained significant attention due to their potential as drug targets. One promising lead is PDLIM1P4, a protein that has been identified as a potential drug target and biomarker for several diseases.

PDLIM1P4 is a protein that is expressed in various tissues, including platelets, macrophages, and neural cells. It is a single-pass transmembrane protein that contains a unique N-terminal region that is composed of a PDL domain and a transmembrane region. The PDL domain is a conserved region that is found in various proteins that are involved in cell signaling and signaling pathways. The transmembrane region is responsible for the protein's localization and retention in the cell membrane.

PDLIM1P4 has been shown to play a role in several physiological processes, including blood clotting, thrombosis, and immune regulation. For example, studies have shown that PDLIM1P4 is involved in platelet function and contributes to the stability of platelet aggregates. Additionally, PDLIM1P4 has been shown to play a role in immune regulation, including the regulation of T cell proliferation and the response to infection.

As a potential drug target, PDLIM1P4 has been the focus of several research studies. Studies have shown that PDLIM1P4 can be targeted by small molecules, including inhibitors of platelet aggregation and inhibitors of the PDL domain. Additionally, several clinical trials are underway to evaluate PDLIM1P4 as a potential drug candidate for various diseases, including cardiovascular disease, cancer, and neurological disorders.

As a biomarker, PDLIM1P4 has been shown to be a useful marker for several diseases, including cardiovascular disease and cancer. Studies have shown that PDLIM1P4 levels are elevated in individuals with cardiovascular disease and that they are also increased in individuals with certain types of cancer. This suggests that PDLIM1P4 may be a useful biomarker for these diseases and could potentially be used for diagnostic purposes.

In conclusion, PDLIM1P4 is a protein that has been shown to play a role in several physiological processes, including blood clotting, thrombosis, and immune regulation. As a potential drug target, PDLIM1P4 has the potential to be used for the treatment of a wide range of diseases. Additionally, PDLIM1P4 has also been shown to be a potential biomarker for several diseases, including cardiovascular disease and cancer. Further research is needed to fully understand the role of PDLIM1P4 in these diseases and to develop safe and effective treatments.

Protein Name: PDZ And LIM Domain 1 Pseudogene 4

The "PDLIM1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDLIM1P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets